Once-Weekly Insulin Added To Novo Nordisk’s Clinical Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk is evaluating new long-acting and quick-acting insulins in clinical trials as competitive pressure looks set to intensify in 2013 for its market-leading GLP-1 agonist, Victoza.
You may also be interested in...
Business News, In Brief
Novo Nordisk and Allergan both report setbacks during their respective first quarter earnings calls. Meanwhile, Valeant and Actavis avoid speculation about a potential merger, and other Q1 happenings.
Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.
Emerging Markets Earnings Roundup: Merck And Novo Nordisk
In this earnings round up, we zoom in on Merck and Novo Nordisk’s performance in emerging markets for 2012.